Data usage agreement & data access
By downloading any of the summary statistics provided by omicscience.org, you agree to the following conditions.
Please read these licence terms carefully.
Disclaimer statement
- These data are provided on an “as-is” basis, without warranty of any type, expressed or implied, including but not limited to any warranty as to their performance, merchantability, or fitness for any particular purpose.
- Investigators will use these results for scientific research and educational use only, use for commercial businesses is not permitted.
- Investigators will not include these results in meta-analyses of any kind for single or more entities (protein targets/metabolites) without explicit written consent and/ or a collaborative agreement with the respective data owners (corresponding author(s)).
- Reposting or distribution of omicscience results files is prohibited.
- Investigators certify that they are in compliance with all applicable local, state, and federal laws or regulations and institutional policies regarding human subjects and genetics research.
- Investigators will never attempt to identify any participants.
- Investigators will cite the appropriate omicscience publications, this resource (www.omicscience.org) and respective acknowledgements
in any communications or publications arising directly or indirectly from these data. In addition, please acknowledge the time and effort of the
study participants and investigators whose data has enabled this research by including the respective study DOI and information:
EPIC-Norfolk - DOI 10.22025/2019.10.105.00004; https://www.epic-norfolk.org.uk/
Fenland - DOI: 10.22025/2017.10.101.00001; https://www.mrc-epid.cam.ac.uk/research/studies/fenland/
INTERVAL - DOI: 10.1016/S0140-6736(17)31928-1; https://www.intervalstudy.org.uk/
Access to full summary statistics
Result files can be downloaded directly via omicscience.org. For larger files (>1TB) we are currently working on a solution to facilitate easy access via web or programmatically.
| Author | Year | Publication | Description | Download |
|---|---|---|---|---|
| Koprulu et al. | 2023 | Proteogenomic links to human metabolic diseases. | pGWAS study of 2,923 plasma proteins (Olink Explore 1536 and Explore Expansion assays) in participants from the EPIC-Norfolk Study. |
in progress |
| Surendran*, Stewart* et al. | 2022 | Rare and common genetic determinants of metabolic individuality and their effects on human health. |
mGWAS study of 913 blood metabolites assayed in participants from the EPIC-Norfolk and INTERVAL Study. |
in progress |
| Pietzner et al. | 2021 | Mapping the proteo-genomic convergence of human diseases. | pGWAS study of 4,775 plasma proteins (SomaScan v4 platform) in participants from the Fenland Study. |
syn51761394 |
| Pietzner et al. | 2021 | Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. |
mWAS investigating the association of 1,014 blood metabolites with 27 incident diseases, all-cause mortality and disease multimorbidity in participants of the EPIC-Norfolk cohort. |
omicscience |
| Lotta*, Pietzner* et al. | 2021 | A cross-platform approach identifies genetic regulators of human metabolism and health. |
mGWAS study (cross-platform, meta-analyses) of 174 blood metabolites across six cohorts. |
omicscience |
| Pietzner et al. | 2020 | Genetic architecture of host proteins involved in SARS-CoV-2 infection. | pGWAS study of 179 COVID-19-relevant host proteins (SOMAscan v4 platform) in participants from the Fenland Study. |
omicscience |